Skip to content
StockMarketAgent
Direct answer
DHR trades against a final fair-value range of $122.72-$203.68, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $123, high $204, with mid-point at $163.
Stock analysis

DHR Danaher Corporation fair value $163–$204

DHR
By StockMarketAgent.AI team· supervised by
Analizzato: 2026-05-10Prossimo aggiornamento: 2026-08-10Methodology v2.4Archetype: Mature compounderNYSE · Health Care
View archive
Prezzo
$171.16
▼ -8.06 (-4.71%)
Valore equo
$163
$163–$204
Valutazione
Mantenere
confidence 87/100
Potenziale rialzo
-4.7%
upside to fair value
Margine di Sicurezza
$138.63
buy below · 15%
Capitalizzazione
$121.1B
P/E fwd 18.8
Fallback in ingleseIT
Mostrando la fonte in inglese mentre traduciamo
Questo report non è ancora stato tradotto. Aggiorna tra qualche minuto una volta che la coda di traduzione avrà recuperato.

§1 Sintesi

  • Composite fair value $163 with high case $204.
  • Implied downside of 4.7% to fair value.
  • Moat 9/10 · confidence 87/100 · Mature compounder.
  • Trades close to fair value, so the margin of safety is limited either way.
Fair value
$163
Margin of safety
-4.9%
Confidence
87/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$171.16Price
FV $163.1
High $203.68

DHR trades against a final fair-value range of $122.72-$203.68, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Intangible Assets
    Intangible Assets
  • Switching Costs
    Switching Costs
  • Bull thesis
    Intrinsic valuation suggests downside risk.

§2 Scenario ribassista

Under severe bioprocessing market contraction and failed M&A execution, our pure intrinsic models force valuation toward the $114-$122 range. Margins revert below 19% as DBS efficiencies fail to offset volume deleverage, and the terminal multipleTerminal multipleThe exit P/E or EV/EBITDA we apply to the final year of an explicit forecast. Anchored to the business's long-run quality and the prevailing risk-free rate. contracts toward 15x as the compounding narrative breaks.

Come questa tesi può fallire

Prolonged Bioprocessing Slump

· High

Extended pharma funding constraints and destocking cap revenue growth in low single-digits.

FV impact
-25%

M&A Integration Failure

· Medium

A major acquisition fails to realize DBS synergies, destroying ROIC and stalling margin expansion.

FV impact
-15%

China Market Deterioration

· Medium

Deepening macro weakness and localized competition in China structurally erode regional market share and profitability.

FV impact
-10%
Segnali di allerta precoce da monitorare
MetricaAttualeSoglia di attivazione
Consumables growth turning negativeMonitorDeterioration versus the report thesis
Operating margin contracting below 19%MonitorDeterioration versus the report thesis
Unexplained delays in M&A integration milestonesMonitorDeterioration versus the report thesis
Rising days sales outstanding in emerging marketsMonitorDeterioration versus the report thesis
CapEx to depreciation ratio falling below 0.75MonitorDeterioration versus the report thesis

§3 Storia finanziaria

Conto economico — ultimi sei periodi
VoceT−0T−1T−2T−3T−4CAGR
Periodo2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
Ricavi$24.80B$26.64B$23.89B$23.88B$24.57B-0.2%
Utile lordo$15.24B$16.19B$14.03B$14.21B$14.52B-1.2%
Reddito operativo$6.39B$7.54B$5.20B$4.86B$4.69B-7.4%
Utile netto$6.43B$7.21B$4.76B$3.90B$3.61B-13.4%
EPS (diluito)$9.66$6.38$5.29$5.05-15.0%
EBITDA$8.80B$9.48B$7.50B$7.28B$6.95B-5.8%
R&S$1.50B$1.53B$1.50B$1.58B$1.60B+1.6%
SG&A$6.81B$7.12B$7.33B$7.76B$8.24B+4.9%

Punteggi di qualità

Piotroski F-score
5 / 9
Composito qualità 0–9
Altman Z-score
3.69
Rischio di fallimento (>3 sicuro)
Beneish M-score
-2.57
Rischio di manipolazione degli utili
OCF / Utile netto
1.78×
>1 indica alta qualità degli utili
Soglia di qualità contabile
Pass
Soglia corretta per settore
ROIC
4.9%
Rendimento del capitale investito
Sezione 3

Numbers analysis

Allocazione del capitale

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Abbonati individuali — da §4 in poi11 sezioni in più

Leggi l'analisi completa — 11 sezioni in più.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Report completo per ogni ticker coperto
24 mesi di archivio rating
Briefing della watchlist + avvisi di variazione del rating
Esportazione PDF + DOCX in qualsiasi lingua
Inizia la prova gratuita
Annulla in qualsiasi momento.
FAQ

DHR — frequently asked questions

  1. Based on our latest analysis, DHR trades close to fair value. The current price is $171 versus a composite fair-value midpoint of $163 (range $123–$204), which implies roughly 4.7% downside to the midpoint.
Related coverage

Names readers of DHR also follow

Same archetype: mature-compounder
Same sector: Health Care